India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
New research labs and process development services to enable next generation therapeutics
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Subscribe To Our Newsletter & Stay Updated
